View Cart (0 items)

Pharmaceutical

New heart failure drug could cut deaths by 20%

No Comments
Swiss pharmaceuticals group Novartis is planning to launch a new drug that has the potential to cut cardiovascular death and admissions to hospital by 20%.
Read More

New facility to research personalized cellular cancer therapies

No Comments
A new facility to develop personalized cellular cancer therapies will be built by the University of Pennsylvania, funded in part with a $20 million investment from Novartis.
Read More

Global pharmaceutical sales projected to reach $1 trillion in 2014

No Comments
The outlook for the pharmaceutical industry is bright, according to a new report that identifies a number of positive trends.
Read More

GSK recalls batches of Eye-Mo solution

No Comments
London-listed pharmaceuticals giant GlaxoSmithKline (GSK) has launched a voluntary recall of several batches of its Eye-Mo Red Eyes Formula Ophthalmic Solution.
Read More

GSK to start clinical trials on new Ebola vaccine

No Comments
London-listed pharmaceuticals company GlaxoKlineSmith will start clinical safety trials for its experimental Ebola vaccine in the U.S. as early as next week.
Read More

Roche acquires InterMune for $8.3 billion in move to strengthen respiratory portfolio

No Comments
Swiss pharmaceuticals group Roche revealed this week that it has agreed to acquire California-based biotechnology company InterMune Inc. in a deal worth $8.3 billion.
Read More

Tighter restrictions to be placed on hydrocodone combination products

No Comments
Medicines containing hydrocodone, a highly addictive painkiller, will be subject to more restrictions under new rules published by the U.S. Drug Enforcement Administration (DEA) this week.
Read More

FDA warns consumers to avoid fraudulent Ebola treatment products

No Comments
The agency said that it had seen and received consumer complaints about various products being offered online that are claimed to either prevent the Ebola virus or treat the infection.
Read More

Sanofi, MannKind agree on $925 million deal for inhaled insulin therapy

No Comments
Under the exclusive agreement with MannKind Corporation the two companies will collaborate on development and commercialization of Afrezza (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes.
Read More

Alvogen acquires South Korea's Dream Pharma

No Comments
Pharmaceutical company Alvogen has agreed to purchase Dream Pharma, based in South Korea, for $187 million in cash.
Read More